哌拉西林他唑巴坦治疗金黄色葡萄球菌肺炎42例临床剖析.docVIP

哌拉西林他唑巴坦治疗金黄色葡萄球菌肺炎42例临床剖析 　　[摘要] 目的 探讨哌拉西林他唑巴坦治疗金黄色葡萄球菌肺炎42例临床分析。 方法 方便选取2016年1月―2017年5月该院收治的42例金黄色葡萄球菌肺炎患者作为试验组，采用哌拉西林他唑巴坦治疗。同期将该院42例采用克林霉素治疗金黄色葡萄球菌肺炎患者作为对照组。比较两组患者临床疗效的差异，并分析其细菌清除率情况。 结果 试验组患者临床痊愈率、总有效率分别为54.7%、95.2%高于对照组26.2%、76.2%，比较差异有统计学意义（P0.05）；试验组患者细菌清除率高于对照组，分别为73.8%、50.0%，比较差异有统计学意义（P0.05）；试验组患者不良反应发生率为4.8%低于对照组23.8%，比较差异有统计学意义（P0.05）。结论 哌拉西林他唑巴坦治疗金黄色葡萄球菌肺炎效果佳，其临床有效率高，细菌清除率好，不良反应少，值得临床选择。 　　[关键词] 哌拉西林他唑巴坦；金黄色葡萄球菌；肺炎；临床分析 　　[中图分类号] R259 [文献标识码] A [文章编号] 1674-0742（2018）01（b）-0124-03 　　[Abstract] Objective To study the clinical analysis of piperacillin tazobactam in treatment of 42 cases with staphylococci aureus pneumonia. Methods 42 cases of patients with staphylococci aureus pneumonia admitted and treated in our hospital from January 2016 to May 2017 were convenient selected as the test group， which were treated with piperacillin tazobactam， while 42 cases in the control group were treated with clindamycin at the same period， and the clinical curative effect was compared between the two groups， and the bacterial clearance rate was analyzed. Results The clinical cure rate and total effective rate in the test group were higher than those in the control group（54.7%， 95.2% vs 26.2%， 76.2%）， and the differences were statistically significant（P0.05）， and the bacterial clearance rate in the test group was higher than that in the control group， （73.8% vs 50.0%）， and the difference was statistically significant（P0.05）， and the incidence rate of adverse reactins in the test group was lower than that in the control group， （4.8% vs 23.8%）， and the difference was statistically significant（P0.05）. Conclusion The effect of piperacillin tazobactam in treatment of staphylococci aureus pneumonia is good with high clinical effective rate， good bacterial clearance rate and few adverse reactions， and it is worth clinical selection. 　　[Key words] Piperacillin tazobactam； Staphylococci aureus pneumonia； Pneumonia； Clinical analysis 　　肺炎是临床上较为常见的呼吸道感染性疾病之一，随着抗生素的广泛使用，其发病